Pfizer Returns Bavencio Rights To Merck KGaA, Closing An IO Era
Executive Summary
The arrangement ends a nearly 10-year collaboration between Pfizer and Merk KGaA on the PD-L1 inhibitor that, despite some success, never reached its ultimate goal.
You may also be interested in...
Five Late-Breakers To Look Out For At ESMO
The upcoming European Society for Medical Oncology meeting in Madrid has a full slate of potentially practice-changing late-breaking clinical trials ready to be presented. Here, Scrip takes a look at five of the most eagerly anticipated.
Stock Watch: Hierarchies Of Drugs Against The Same Target
Rarely does the best-selling product emerge when a newer antibody platform is used to improve on a successful earlier-generation product. Better to play to the platform’s strengths.
Merck’s Keytruda And Seagen’s Padcev Become First PD-1/ADC Combo To Win US Approval
The blockbuster PD-1 inhibitor and antibody-drug conjugate will be used to treat a subset of first-line urothelial carcinoma patients considerably widening Padcev’s market, but rates of peripheral neuropathy with the combination have left some analysts concerned.